Clinical trials: Antiplatelet Effect
Myocardial Infarction Type 2
Effect of Classic Secondary Prevention in Type 2 MI: A Target Trial Emulation Study
A classic heart attack is caused by a blockage to the coronary arteries that supplies the heart muscle with oxygenated blood. The medical term for this condition is type 1 myocardial infarction.
- Trial name
- NCT06736353
- Testing
- Beta Blocker Therapy or No Therapy (Control), RAAS blocker Therapy or No therapy (Control), Statin Therapy or No Therapy (Control)
- Where
- Sweden
- Volunteers
- 14,000 people
- Sponsor
- Uppsala University
Unstable Angina
Influence of METHoxyflurane on ANtiplatelet Effect of Ticagrelor in Patients With Unstable Angina Pectoris
The purpose of this study is to evaluate differences in the pharmacokinetics and pharmacodynamics of ticagrelor and its active metabolite in patients who received ticagrelor followed with methoxyflurane versus ticagrelor followed…
- Trial name
- METHANE (NCT04442919)
- Testing
- Ticagrelor followed with Methoxyflurane, Ticagrelor followed with Morphine, Ticagrelor alone
- Where
- Poland
- Volunteers
- 72 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Platelet Dysfunction Due to Drugs
The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease
This study aims to assess the effects of low dose ticagrelor on platelet function testing in patients with stable coronary artery disease.
- Trial name
- TWIST (NCT04206176)
- Testing
- Ticagrelor
- Where
- Trinidad and Tobago
- Volunteers
- 25 people
- Sponsor
- The University of The West Indies
Coronary Disease
Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel
This study is designed to test the hypothesis that the onset of the antiplatelet effect 90mg-first-dose of ticagrelor will be more rapid and greater than 300mg-loading-dose of clopidogrel evaluated by P2Y12 reaction units…
- Trial name
- NCT02513004
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yongjian Wu
Acute Coronary Syndrome
Study of LC23-1306 in Healthy Male Subjects
This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic/pharmacodynamic characteristics.
- Trial name
- NCT01526577
- Testing
- LC23-1306, Ticagrelor
- Where
- South Korea
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Type 2 Diabetes Mellitus
Evaluation of Antiplatelet Effects of Different Dosages of Aspirin in Type 2 Diabetic Patients
The efficacy of low dose aspirin appears to be substantially lower in diabetic patients, compared to patients without diabetes. The aim of the investigators study is to test the laboratory response to different dosing of aspirin…
- Trial name
- DM-ASA 001 (NCT00812032)
- Testing
- Aspirin
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Karolinska Institutet
Acute Coronary Syndromes, Percutaneous Coronary Intervention
Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation
Clopidogrel resistance (CR) or low-responsiveness is associated with increased risk of ischemic events and can be detected by laboratory tests.
- Conditions
- Acute Coronary Syndromes, Percutaneous Coronary Intervention, Clopidogrel Low Responsiveness
- Trial name
- NCT01094457
- Testing
- aspirin, clopidogrel, aspirin, clopidogrel, cilostazol
- Where
- 3 sites in China
- Volunteers
- 840 people
- Sponsor
- Shenyang Northern Hospital
Coronary Heart Disease
Pharmacodynamic and Short-term Effects of Half-dose Ticagrelor With or Without Aspirin vs DAPT From Day of PCI in CCS
Six months of aspirin plus clopidogrel remains the recommended antiplatelet regimen after percutaneous coronary intervention (PCI) for chronic coronary syndrome (CCS), with the more potent P2Y₁₂ inhibitors reserved for the acute…
- Trial name
- NCT07622056
- Testing
- Aspirin 100 mg + clopidogrel (300 mg load → 75 mg daily) ×6 months, then aspirin monotherapy, Aspirin 100 mg + ticagrelor (90 mg load → 45 mg twice daily) ×6 months, then aspirin monotherapy, Ticagrelor (90 mg load → 45 mg twice daily) monotherapy; aspirin stopped at day 2 after randomisation; continued indefinitely
- Where
- Taiwan
- Volunteers
- 54 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Peripheral Arterial Disease
Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease
This investigation will be conducted in subjects >18 years of age with PAD. Platelet activation and aggregation, and biomarkers associated with platelet activation, oxidative stress, and inflammation will be assessed prior to…
- Trial name
- NCT03247972
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Inova Health Care Services
Antiplatelet Effect
Does Pantoprazole Reduce the Anti-platelet Effect of Clopidogrel?
The investigators sought to evaluate the influence of pantoprazole, indicated as less effective than other proton pump inhibitors, on the antiplatelet effect of clopidogrel, with stratification of the population according to the…
- Trial name
- NCT02733640
- Testing
- Pantoprazole, Ranitidine
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Seoul National University Bundang Hospital
Coronary Artery Disease
Impact of Hybrid Coronary Revascularization on Antiplatelet Therapy
The effect of antiplatelet therapy is impaired among patients, who recently underwent on-pump coronary artery bypass grafting. The impact of hybrid coronary revascularization using minimal invasive surgical techniques on the…
- Trial name
- NCT02293928
- Testing
- Hybrid coronary revascularization
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Aarhus University Hospital Skejby
Drug Effect Disorder, Platelet Procoagulant Activity Deficiency
the Effect Between Platelet Reactivation and Antiplatelet Drugs
Different antiplatelet drugs played various role in coronary artery disease. The mechanisms were unclear. Platelet reactivation maybe was one of major causes.
- Trial name
- NCT02198053
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Beijing Anzhen Hospital
Ischemic Preconditioning
A Trial Comparing the Ischemic Preconditioning Effects of Ticagrelor and Clopidogrel in Humans
Antiplatelet therapy remains a cornerstone in the treatment of acute and chronic coronary artery disease. Aspirin was the first such therapy to prove its benefits in acute myocardial infarction.
- Trial name
- ETCH (NCT01743937)
- Testing
- Coronary occlusion with balloon inflation
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Texas Southwestern Medical Center
Antiplatelet Aggregation
A Study to Evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent Implantation in Non-diabetic Patients
The purpose of the study is to look at the biomarkers of inflammation and platelet activation in patients with drug eluting stents implanted approximately 12 months ago on aspirin and statin, for a 4-week period after the routine…
- Trial name
- DECADES (NCT00493779)
- Testing
- Blood Collection
- Where
- 6 sites in France, Germany and 2 more
- Volunteers
- 103 people
- Sponsor
- Bristol-Myers Squibb
OGD, Gastric Ulcer Induced by Anti-platelet Agent
Effect of Second-look Endoscopy on Peptic Ulcer Rebleeding in Patients With Early Resumption of Antiplatelet Agents
OBJECTIVES: Up to 15% of patients with peptic ulcer bleeding will develop rebleeding, mainly in those with ulcers of higher-risk stigmata (i.e. Forrest class Ia to IIb).
- Conditions
- OGD, Gastric Ulcer Induced by Anti-platelet Agent, Duodenal Ulcer Induced by Anti-platelet Agent
- Trial name
- NCT02840929
- Testing
- Second-look OGD, Esomeprazole
- Where
- 2 sites in China, Hong Kong
- Volunteers
- 2 people
- Sponsor
- The University of Hong Kong
Stable Coronary Artery Disease
A Pharmacodynamic Study With Ticagrelor in African American Patients
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in African American patients with stable coronary artery disease.
- Trial name
- NCT01523392
- Testing
- Ticagrelor, Clopidogrel
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Ischemic Heart Disease, Osteoarthritis
Celecoxib, Ibuprofen and the Antiplatelet Effect of Aspirin
Study design: Single center, placebo-controlled, double blind, parallel groups. To evaluate the potential interaction between aspirin and ibuprofen or celecoxib in patients with osteoarthritis (OA) and documented stable ischemic…
- Trial name
- NCT00565500
- Testing
- celecoxib, ibuprofen
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- University of Chieti
Acute Coronary Syndrome
Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial
Dual antiplatelet therapy with aspirin and Clopidogrel for at least one year is essential in patients following an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) with drug eluting stent(s.
- Trial name
- RESET GENE (NCT01465828)
- Testing
- Clopidogrel, prasugrel
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Gennaro Sardella
Platelet Aggregation Inhibitors
The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke Patients
Background: Clopidogrel, an antiplatelet prodrug, is widely used for prevention of the recurrent cardiovascular events. CYP2C19 is one of the crucial enzymes for the activation of clopidogrel.
- Trial name
- NCT02711410
- Testing
- Clopidogrel
- Volunteers
- 518 people
- Sponsor
- National Cerebral and Cardiovascular Center, Japan
Hemorrhage, Cerebrovascular Accident
Antiplatelet Therapy Continuation in Spine Surgery - Its Effect on Postoperative Morbidity and Mortality
The objective of this study is to evaluate the safety of antiplatelet (APA)therapy continuation in patients undergoing lumbar spine surgery (laminectomy, discectomy and foraminotomy), and to gather evidence-based data regarding…
- Conditions
- Hemorrhage, Cerebrovascular Accident, Myocardial Infarction, Pulmonary Embolism
- Trial name
- NCT01006083
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Tel-Aviv Sourasky Medical Center